Role of Angiotensin Peptides Precursor in Ethanol Mediated Hepatotoxicity: Perspective on Angiotensinogen

Rais A. Ansari*,1, Syed A. A. Rizvi1, Kazim Husain2 and Natalia Osna3

1Department of Pharmaceutical Sciences, College of Pharmacy, Health Professions Division, Nova Southeastern University, 3200 S University Drive, Fort Lauderdale, FL 33328, USA
2Department of Physiology, Pharmacology and Toxicology, PO Box 7004, Ponce School of Medicine Ponce, PR 00732-7004, USA
3Department of Internal Medicine, GI Section University of Nebraska Medical Center, VA Medical Center, 4101 Woolworth Ave, Omaha, NE 68105, USA

Abstract: Alcohol usage poses serious social and economical challenges. Its overuse is responsible for loss of billions of dollars due to fatal accidents and causes multiple diseases. Chronic alcoholism leads to liver disorders, including steatosis, hepatitis, fibrosis and cirrhosis. Both binge and chronic alcohol drinking result in blood pressure elevation and hypertension. As a significant mechanism, changes in the levels of angiotensinogen-released peptides play an important role in advanced alcohol liver disease. This review summarizes some of the studies that have demonstrated their role in liver fibrosis, cirrhosis and hypertension. Further, the individual variants and polymorphic sites may play a role in alcohol-mediated regulation of angiotensinogen. Possible role of human angiotensinogen on alcohol hepatotoxicity is also discussed.

Keywords: Alcohol, toxicity, fibrosis, angiotensinogen, regulation, hypertension.

INTRODUCTION

Alcoholism leads to severe, often fatal liver diseases, and costs society many billions of dollars each year. Chronic alcohol consumption leads to hepatosteatosis, steatohepatitis, fibrosis, cirrhosis, as well as hypertension. Progression of hepatosteatosis and steatohepatitis to fibrosis and cirrhosis represents advanced stages of the alcohol liver disease [ALD]. ALD is the major cause of end-stage liver disease requiring liver transplantation to prevent death [1, 2]. Sustained consumption of more than 2 drinks [30–50g ethanol] daily raises blood pressure [3-5]. Chronic alcoholism activates resident Kupffer cells and elevates cytokines levels such as tumor necrosis factor-alpha [TNFα] and interleukins, IL-1β, IL-6, and IL-8 [2]. TNFα activates nuclear factor-kappa B [NF-kB] signaling regulating hepatocyte death, while other cytokines activate hepatic stellate cells [HSC] leading to fibrosis and cirrhosis [6]. Studies have demonstrated that blocking the action of Angiotensin II [Ang II] provides protection against the progression of liver towards fibrosis and cirrhosis. In this review, we will focus on the role of Ang II and its precursor, angiotensinogen in alcohol-mediated liver fibrosis, cirrhosis and hypertension.

There are many cellular and molecular events accompanying chronic ALD and hypertension. Fibrosis is initiated after parenchymal necrosis, followed by inflammation [7]. Kupffer cells, the liver resident macrophages, are activated by increased circulating endotoxin. The endotoxin levels are enhanced by alcohol due to increased absorption from intestine after the death of gut bacteria. Activated Kupffer cells then secrete TGF-β1, IL-1, IL-6, IL-8, and TNFa [8]. Cytokines activate HSCs, which increase collagen gene expression and expression of extracellular matrix molecules leading to fibrosis. Dying parenchymal cells induce inflammation, fibrosis, capillarization of sinusoids and increased extracellular matrix [ECMs] formation [9]. This causes elevated resistance and portal hypertension [10]. Depending upon the scale of injury, the host response is either restricted to HSC and Kupffer cells, or to a systemic acute phase response [APR], in which infiltration of immune cells occurs. In transformation of liver from steatohepatitis to fibrosis and cirrhosis, the renin-angiotensin system [RAS] plays a significant role. The production of active peptides from precursor, angiotensinogen involves both classical and alternate pathways. In a classical pathway, renin clips of N-terminal 10 amino acids [angiotensin I [Ang I]] from precursor AGT [11, 12]. Ang I is converted into an octapeptide by clipping off 2 carboxyl terminal amino acids producing Ang II by angiotensin I converting enzyme [ACE]. Ang II is a biologically active endocrine hormone, which functions as a cytokine as well. In addition to classical pathways of production of Ang II, another homologue of ACE, ACE2, two clips of one amino acid from carboxyl ends of Ang I to produce Ang 1-9 [13]. From Ang 1-9, Ang 1-7 is produced that possess opposite biological effects compared with Ang II [13-16]. Ang II can also be converted into Ang 1-7 by ACE2 [17, 18]. Similarly, Ang I and Ang 1-9 can be converted to Ang 1-7 [13].
Production of Ang 1-7 and its opposite biological effects as compared to Ang II constitutes another axis or alternate pathway of angiotensins action [16, 19, 20]. A schematic presentation of pathways for production of biologically active peptides from precursor AGT is depicted in Fig. (1).

Ang II binds to angiotensin type I and type II receptor [AT₁R and AT₂R] while Ang 1-7 binds to Mas receptor which is an oncogene. Production of Ang 1-7 provides neuroprotective, cardioprotective, and hepatoprotective effects [16, 19, 20]. ACE2 also serves as the receptor of severe acute respiratory syndrome [SARS] virus glycoprotein [21].

**PATHOPHYSIOLOGY**

In a diseased liver, the classical RAS [Ang II, AT₁R, renin and ACE] as well as alternative pathways [Ang 1-7, ACE2 and Mas receptor] are upregulated [6]. Ang II increases TGF-β1 and ROS production in liver. TGFβ-1 induces HSC activation, which activates further secretion of TGFβ-1. Abrogation of Ang II effects offers protection against chemical and viral induced hepatic injury, and fibrosis. Blockade of Ang II pathway decreases carbon tetrachloride [CCL4], the classical hepatotoxicant-induced fibrogenesis of the liver. AGT expression is increased in early stage of hepatic fibrosis in CCL4-induced liver fibrosis in rats [22]. Both local and circulating Ang II activation may mediate the response to liver injury [23, 24]. In animal models of fibrosis and cirrhosis, blocking the production of Ang II from the precursor, angiotensin I [Ang I] by inhibiting ACE, protects the liver from becoming fibrotic [6, 8]. Blocking the effects of Ang II at the AT₁R level with selective inhibitors also blocks the fibrotic progression [6, 8]. Animal models, in which the AT₁R is knocked out, are resistant to fibrosis and cirrhosis [25, 26]. Systemic infusion of Ang II increases bile duct blockade-mediated liver fibrosis [27]. A pilot study evaluating efficacy of the AT₁R blocker [ARB], losartan provided protective effects against hepatitis C-induced fibrosis [28, 29]. Another ARB, candesartan, improved one fibrotic marker, while it exhibited no effect on three other markers in a 48-week trial of cirrhotic children [30]. Ang II is also implicated in non-alcoholic fatty liver disease via oxidative stress in Ren2 transgenic rats [31]. RAS blockers have anti-fibrotic and anti-cirrhotic potential in hepatitis C and liver transplant patients [32-34]. Role of ACE2 in blocking the development of liver fibrosis is encouraging. Experimental studies demonstrate that ACE2 activation inhibits liver fibrosis in mice. It seems that there is a balance between ACE and ACE2 activities and outcome of liver fibrosis depends upon these activities [35, 36]. In other studies, urinary level of AGT has been linked to severity of chronic kidney disease. It has been found with human patients that urinary AGT levels correlate to urinary level of ATG has been linked to severity of chronic kidney disease. It has been found that human patients that urinary AGT levels correlate to kidney function and increased levels correlate to chronic kidney disease. It has been found that human patients that urinary AGT levels correlate to kidney function and increased levels correlate to tubular atrophy, glomerulosclerosis and tubular fibrosis [37]. Studies with animals demonstrate that uric acid toxins, indoxyl sulphate and p-cresol sulphate activate intrarenal renin-angiotensin-aldosterone system causing increased angiotensinogen expression including other fibrogenic markers [38]. Over expression of catalase which removes oxidative stress prevents hypertension and kidney tubular apoptosis in angiotensinogen transgenic mice [39]. Transcriptional activation of AGT, also plays a significant role in lung fibrogenesis [40].

In addition to its role in hepatoxicant-mediated fibrosis and cirrhosis, the RAS plays a major role in hydromineral
and cardiovascular homeostasis [41]. The octapeptide, Ang II, is a potent vasoconstrictor and AT1 receptor agonist. Recent studies have demonstrated that adenosine monophosphate activated protein kinase (AMPK) is centrally involved in the regulation of hepatic triglycerides, cholesterol and the fatty acid biosynthesis, which is under the transcriptional regulation of sterol regulatory element binding protein (SREBP). SREBPs are a class of transcription factors which are involved in fat and cholesterol regulation. There are three isoforms of SREBPs, SREBP-1a, SREBP-1c and SREBP-2. Both SREBP-1a and 1c, which are alternate spliced forms, are involved in regulation of fatty acid biosynthesis. SREBPs exist as precursor molecules in endoplasmic reticulum and are activated by SREBP cleavage activating protein [SCAP] and site-1 protease [S1P] and site-2 protease [S2P] and their activation is dependent on the cellular cholesterol level. Studies have demonstrated that ethanol exposure of cultured cells leads to increased level of active/nuclear form of SREBP-1 [nSREBP-1]. SREBP activation is dependent on alcohol metabolism and the metabolic product, acetaldehyde is capable of activation of SREBP-1 and the inhibitors of alcohol dehydrogenase [4-methylpyrazole] blocked the SREBP activation in cultured rat hepatocytes and HepG2 cells [60, 61]. SREBP-1c level is increased transcriptionally and by decreased proteasomal degradation of protein in acute and chronic alcohol exposure [62].

Alcohol exposure causes increased gut permeability of endotoxin, which stimulates production of proinflammatory, tumor necrosis factor-α [TNFα] and cytoprotective cytokines [interleukin-6 and 10] from Kupffer’s cells, the resident macrophages. The level of TNFα is increased in chronic alcohol abusers and animal models of alcohol toxicity. The level of interleukins, [IL-1, IL-6 and IL-8] has been found increased in hospitalized patient with ALD and in animal models of alcohol toxicity [63-65]. The increase in IL-6 due to ethanol in patients is the part of the hepatoprotective process. IL-6 and IL-10 activate signal transducer and activator of transcription [STAT3], which is responsible for liver regeneration and provides protection against redox-dependent cell death [66, 67]. Activation of STAT3 causes induction of anti-inflammatory signal to inhibit inflammation during alcohol mediated injury [63]. Hepatic knock out of STAT3 in mice increases hepatosteatosis and increased expression of lipogenic genes after ethanol exposure [68].

Recent studies have demonstrated that adenosine monophosphate activated protein kinase [AMPK] is centrally involved in the regulation of hepatic triglycerides, cholesterol and the fatty acid biosynthesis, which is under the transcriptional regulation of SREBP-1. Recently, it has been established that SREBP-1 is the target of AMPK [69]. Activation of AMPK in hepatocytes caused decreased nSREBP-1 level due to increased proteasomal degradation [70]. Metformin and aminoimidazole-4-carboxamide ribonucleotide [AICAR]
are known activators of AMPK and treatment of hepatoma cells results in decreased nSREBP while ethanol treatment reversed the effects [70]. Therefore, AMPK can play a significant role in ethanol mediated effect on hepatic SREBP-1. This finding has been further substantiated by a recent report that fat derived hormone, adiponectin which is upregulated in ethanol exposure, down regulates AMPK, alleviating alcoholic fatty liver disease [71]. In addition to regulation of lipogenic genes via SREBP-1, ethanol has been shown to alter liver activating protein [LAP] and liver inhibiting protein [LIP] in rats chronically fed with ethanol. Both LAP and LIP are basic helix loop helix transcription factor which bind to CAAT sequences in DNA and are referred as CAAT/enhancer binding protein [C/EBP]. LAP is a full length C/EBP-β which activates liver specific transcription of genes. LIP is the short form of C/EBP-β and inhibits hepatic gene transcription. C/EBPs are activated in endoplasmic reticulum-stress [ER-Stress] and alcohol exposure produces ER-stress [72, 73]. Chronic ethanol exposure in rats causes increase in LAP [C/EBP-β] and reduction in LIP in liver and this increase in LAP vs LIP is responsible for ethanol induced effects [increase] on Class I alcohol dehydrogenase in liver [74].

Oxidative Stress and Cellular Protection

Ethanol is metabolized enzymatically in four compartments: cytosol [alcohol dehydrogenase], mitochondria [aldehyde dehydrogenase], microsome [CYP 2E1] and peroxisome [catalase]. Chronic ethanol ingestion has been shown to induce hepatic CYP2E1 leading to generation of 1-hydroxy ethyl radical. The hepatic oxidative stress relates to induction of reactive oxygen species [ROS] formation and down-regulation of antioxidant enzymes; superoxide dismutase [SOD], catalase [CAT], and glutathione peroxidase [GPX] and endogenous antioxidant , glutathione [75, 76]. Mild to moderate alcohol usage leads to increased hepatic iron-II [Fe+++] levels [77]. The increased Fe++ occurs in Kupffer cells in animal model of ALD [78, 79]. Fe++ and alcohol metabolism in the liver by CYP2E1 produce ROS and hypoxia [80]. Activation of hypoxia-inducible transcription factor-1alpha [HIF-1α] has been observed with ethanol exposure in control and with hepcidin, an iron sensing peptide knockout mice [81, 82]. ROS causes oxidative stress in ethanol metabolizing cells; especially hepatocytes. Reducing ROS is linked to cytoprotection and cell survival. Induction of cytoprotective enzymes in response to increased ROS is regulated at the transcriptional level by a cis-acting antioxidant response element [ARE] after binding of nuclear factor erythroid2-related factor2 [Nrf2]. Initially, ARE sequences were defined with two detoxifying enzymes, glutathione S-transferase A2 and NADPH:quinone oxidoreductase [83].

Regulation of genes via ARE involves the activation of Nrf2 which remains in inactive form in cytoplasm and relocates to nucleus upon activation [84, 85]. Activation of hypoxia inducible transcription factor-1alpha [HIF-1α] is observed in hypoxic and increased ROS states [86]. After activation, HIF-1α activates and/or represses the genes containing hypoxia response element [HRE] [87]. Fatty acid synthase [FAS] gene which is responsible for lipogenesis is upregulated in alcohol exposure as well as in tumor cells which possess hypoxic microenvironments. [88]. The sequence of events of alcohol exposure and its effects are summarized in Table 1.

ROS stimulated expression of AGT in renal cells occurs with IgA induced nephropathy in high serum IgA [HIGA] mice [89]. Activation of AGT by ROS secondary to high glucose levels has also been observed in rat kidney proximal tubule [90]. The level of AGT mRNA increases with binge ethanol exposure [91]. Thus it is becoming evident that ethanol exposure and increased ROS activate AGT transcription. In an animal model, it has been shown that the level of Ang II is increased which corresponds to oxidative stress in endothelial cells in rats exposed to ethanol [92, 93]. Utilizing the

<table>
<thead>
<tr>
<th>Table 1. Sequence of Events after Ethanol Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Order of Events</strong></td>
</tr>
<tr>
<td>Initial</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Subsequent</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Subsequent</td>
</tr>
<tr>
<td>Subsequent</td>
</tr>
<tr>
<td>Subsequent</td>
</tr>
<tr>
<td>Subsequent</td>
</tr>
<tr>
<td>Subsequent</td>
</tr>
<tr>
<td>Subsequent</td>
</tr>
</tbody>
</table>
cell based model, our lab has demonstrated increased AGT secretion from human hepatocytes [94, 95]. The critical question of AGT activation is how these events regulate the hAGT gene during ethanol toxicity.

REGULATION OF HUMAN ANGIOTENSINOGEN AND POSSIBLE ETHANOL EFFECTS

The human AGT gene promoter is located 5'-upstream of the coding sequences while the enhancer region is located at 3' downstream [96]. The human AGT gene proximal promoter nucleotide sequences –1223 to +27 is defined for the possible cis-acting DNA response element for the different transcription factors as shown in Fig. (2). Some of the studies which have been carried out from Kumar lab and others have defined the role of transcription factors which are involved in the regulation of organ specific AGT expression [97]. CAAT enhancer binding protein [C/EBP] family of transcription factors especially C/EBPβ binds to the sequences at –99 to –91 of human AGT gene promoter [98]. In addition, liver specific transcription factor HNF3 binds to the sequences located between +10 and +20 of human gene AGT promoter [99]. Human AGT gene is type II acute phase response protein secreted by liver. Accordingly, there are three sites of acute phase response element [APRE] and one of them is at -278/-269, where IL-6 induced STAT3 binding is responsible for IL-6 induced effects [100]. The differences in the mouse and human AGT promoters are in the APRE. While the mouse AGT is a type I APR and is induced by IL-1 via NF-κB while human AGT is induced by IL-6 via STAT3 [101]. In addition to these defined sites, CREB site is located at –840 and –830 of human AGT promoter [102]. There are at least 3 direct repeats [DRs] sequences in human AGT. DR1 is located between –363 and –423 and is the binding site for HNF4 and HNF4 is capable of binding and expression of human AGT by DR1 [103]. Glucocorticoids play a significant role in the expression of human AGT gene since it is an APR II gene. There are a number [3] of half glucocorticoid response element [GRE [-673, -130 and +15]] and one full GRE at –217 position. Due to the single nucleotide polymorphism [SNP] at –217 [A/G], the –217 position with A substitution becomes a complete palindromic site for GR. The role of GR in transcriptional regulation of human AGT by –217A polymorphism has been demonstrated by Jain et al [104]. The hierarchal regulation of AGT by glucocorticoids observed in mouse is not well defined for human AGT besides the presence of multiple GRES [101]. Similarly, the SNPs at –6 [G/A] and –20 [C/A] also result into binding site for the transcription factor. The –20A SNP leads to the creation of SP1 site and is modulated by estrogen receptor. Orphan nuclear receptor, Arp-1 also binds to the sequences and is capable of disrupting the ER induced effects [105]. In addition to the aforementioned SNP and its significance in the transcriptional regulation of human AGT, a number of other SNPs [-1074 T/G, -793 A/G and -776 C/T] have also been reported. SNP -1074T binds to HNF3β while -1074G lacks the binding ability [97].

CLINICAL SIGNIFICANCE

Polymorphic site -217 A has been shown to bind CEBP-β and glucocorticoids. Similarly, -1074T binds with hepatocyte nuclear factor-3β. As mentioned above that alcohol exposure increases the ratio of LAP vs LIP. Increasing activity of LAP after ethanol exposure is likely to increase the transcription of hAGT. Individuals possessing the -1074T variant may contain increased level of AGT since HNF-3β is liver specific transcription factor. HNF-3β is an orphan transcription factor whose modulation by agonist is not well characterized. SNP-6/A is in linkage disequilibrium with M235T. The role of -6A has been shown to possess higher promoter activity but its mechanism is not known. It is known that individuals with 235T possess increased level of circulating AGT [51]. Studies relating to linkage disequilibrium have observed that SNP -6A, -217A, -776T, -793A and -1074T are in association. Due to higher levels of AGT mediated by -6A, -216A, -1074T, it is anticipated that these individuals will carry in-

Fig. (2). Human AGT proximal promoter structure and single nucleotide polymorphic sites binding site to possible transcription factors.
increased risk of alcohol mediated hepatotoxicity and alcohol mediated hypertension due to possible increase in circulating AGT level.

AGTs are acute phase response proteins. While mouse and rat AGT are acute phase response type I proteins, human AGT is APR type II proteins. In injured and inflamed liver, this organ responds to the cascade activation of APRs. In APR I, liver secretes a set of proteins which is followed by APR II in which another sets of proteins are released. In APR, the level of secreted proteins either increases or decreases. In APR, the level of AGT increases while albumin decreases [106-108]. Mouse and rat AGT are classified as APR I proteins because they response to nuclear factor-kappaB [NF-κB] by tumor necrosis factor-alpha [TNFα] and interleukin-1beta [IL-1β]. APR II proteins are responsive to IL-6 and glucocorticoids. Human AGT was known not to possess NF-κB binding site in the proximal promoter and hence its regulation by TNFα and IL-1β were unknown. Recently, a NF-κB binding site has been reported in the distal promoter of hAGT which is responsive to NF-κB activity in kidney epithelial cells [109]. In case of either binge or chronic alcohol intake, either local response to Kupffer’s cell or systemic response due to infiltration of immune cells to liver, the level of TNFα and IL-1β is increased.

In patients suffering from chronic alcoholism the levels of aforementioned cytokines are increased in the blood. Due to increase in these cytokines, the synthesis and secretion of AGT from hepatocytes are likely to increase. Cytokine, IL-6 activates signal transducer and activator of transcription [STAT3] which activates AGT transcription by binding to APR site of hAGT promoter at -278/-269. Activation of STAT3 occurs due to increased circulating level of IL-6 among chronic alcoholics. The binding site[s] of SREBP, a transcription factor which is increased in hepatocytes after ethanol exposure, has not been established. A TRANSFAC analysis indicate presence of SREBP binding site. Alcohol mediated increase in CEBP/β, SREBP, and activation of NF-kB, HIF-1α, and Nr2 are likely to affect hAGT transcription in liver and affect [increase] its synthesis and secretion thereby affecting the alcohol mediated liver fibrosis and hypertension as depicted in Fig. (3).

CONFLICT OF INTEREST

The author(s) confirm that this article content has no conflicts of interest.

ACKNOWLEDGEMENT

None declared.

REFERENCES


Role of Angiotensin Peptides Precursor in Ethanol Mediated Hepatotoxicity

The Open Gastroenterology Journal, 2012, Volume 6


Ansari RA, Razvi SAA, Clark MA, Eds. Angiotensinogen gene regulation after ethanol exposure in hepatocytes. World Congress on Gastroenterology and Urology; 2012 March 12-14; Omaha, NE: OMICS 2012.


Jain S, Li Y, Patil S, Kumar A. A single-nucleotide polymorphism in human angiotensinogen gene is associated with essential hyper-


